Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00802893 · ClinicalTrials.gov registry record · Phase 2
Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction
A Phase 2 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00802893: Clinical Trial Phase 2 study, sponsored by Johns Hopkins University.
NCT00802893 is a Phase 2 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00802893, a Phase 2 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study is designed to assess the safety and efficacy of twice-daily oral dosing of 6R-BH4 to improve endothelial function, reduce systolic blood pressure and reduce arterial stiffness.
Interventions
- OTHER Placebo
- DRUG 6R-BH4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00802893
The ClinicalTrials.gov registry entry for NCT00802893 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00802893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00802893 about?
NCT00802893 is a clinical study titled "Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction". This study is designed to assess the safety and efficacy of twice-daily oral dosing of 6R-BH4 to improve endothelial function, reduce systolic blood pressure and reduce arterial stiffness.
What is the current status of trial NCT00802893?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2008-12. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00802893?
The interventions under investigation include: Placebo (OTHER), 6R-BH4 (DRUG).
Who is sponsoring clinical trial NCT00802893?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.